Oct. 26 at 4:05 PM
Some
$ANVS shareholders have expressed interest in something that I worked on last year. I am tagging
$SAVA because this was a topic of discussion between myself and the CEO of Annovis Bio. I am also tagging
$BCRX because quite a few investors also made large investments into Dr. Maccecchini's company (in some part) based on bio99's many bullish posts covering both the science and his target price projections in the near future back in 2021.
Also, I want to acknowledge @kevindenver for the conversations we have had and especially to @MayoMobile for his outstanding work covering various biotech companies in this space. Both of you were mentioned in my communications with CEO Maccecchini as an example of the Corp de Esprit regarding your shared conviction in Anavex Life Sciences.
What you are about to see is my answer to Dr. Maccecchini regarding her complaint about how ineffective Dr. Marwan Sabbagh's explanation was regarding the mechanism of action (MOA) of Anavex's lead asset, blarcamesine. I discussed the urgent need IMO of an explanation of the MOA for Annovis' lead asset, buntanetap.
My comments attached on this 70-page online file were done quickly and I apologize for any errors you might see. If anyone notices any inaccuracies, please let me know and I would be happy to make corrections.
Thank you all!
P.S. I decided to stop at 70 pages, but there is so much more information. I would not be surprised if such a file would be many tens of thousands of pages long if/when all of the former Annovis Bio CFOs, and others, are involved.
https://www.canva.com/design/DAG21zvqskA/CcwU6Rl5oYSjhvEVFEq50Q/view?utm_content=DAG21zvqskA&utm_campaign=designshare&utm_medium=link&utm_source=viewer